This is a working overview of c-Met signaling, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-23 and is reviewed periodically as new material appears.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
== Development == A cooperative Half-Life game was first alluded to by publisher Sierra On-Line in November 2000 with the announcement of a PlayStation 2 version of Half-Life. At the time, however, it was unclear how a cooperative version of Half-Life would be implemented; the developers, Gearbox Software, were still experimenting with finding the most balanced number of players to build a cooperative game around. By E3 2001, the game had acquired the title Decay, named after the scientific concept of exponential decay for consistency with the scientific names used by previous Half-Life titles. While the E3 convention only provided a demonstration of the main Half-Life PlayStation 2 game, further details were released relating to Decay's premise and story, as well as confirming that the cooperative mode was to be designed for two players. The game's use of new model sets were also showcased. These new models were updated versions of Gearbox's High Definition pack for Blue Shift, featuring higher numbers of polygons and animation features such as facial expressions. The enhanced models were around twice as detailed as those in the High Definition pack, which itself was of a much higher quality than the original models in Half-Life. Media updates through the months following E3 showed various screenshots and the trailer to the game. On August 18, 2001, Sierra announced that Decay was nearly complete, and would be submitted to PlayStation 2 manufacturer Sony for verification within days.
The beta decay of 3H to 3He releases an electron and an antineutrino, and about 18 keV of energy. This is a low-energy decay, so the radiation cannot permeate skin. Tritium is thus only hazardous if directly ingested or inhaled.
=== Private jet controversy === In April 2026, Ford's government purchased a $28.9 million Bombardier 650 luxury private jet, intended to be used by the premier for travel. After backlash from the public and opposition parties, the government announced their intention to sell the jet.
As a result of the increasing popularity of LED light therapies for skin improvements, a wide range of skincare devices utilizing this technology are readily available on the market. LED red light products are most common for domestic LED light therapy, including LED light masks, panels, handheld devices, and belts. Typically, individuals buy these items to address issues like wrinkles and acne, reduce puffiness, and promote hair growth.
The composition and destructiveness of SASP depends upon the senescent cell type, the surrounding microenvironment, and the type of stimulus inducing the senescence. Senescent cells are highly metabolically active, producing large amounts of SASP, which is why senescent cells consisting of only 2% or 3% of tissue cells can be a major cause of aging-associated diseases. SASP factors cause non-senescent cells to become senescent. SASP factors induce insulin resistance. SASP disrupts normal tissue function by producing chronic inflammation, induction of fibrosis and inhibition of stem cells. Transforming growth factor beta family members secreted by senescent cells impede differentiation of adipocytes, leading to insulin resistance. SASP factors IL-6 and TNFα enhance T-cell apoptosis, thereby impairing the capacity of the adaptive immune system. SASP factors from senescent cells reduce nicotinamide adenine dinucleotide (NAD+) in non-senescent cells, thereby reducing the capacity for DNA repair and sirtuin activity in non-senescent cells. SASP induction of the NAD+ degrading enzyme CD38 on non-senescent cells (macrophages) may be responsible for most of this effect. By contrast, NAD+ contributes to the secondary (pro-inflammatory) manifestation of SASP. Aged macrophages have a marked increase in SASP components. Bone marrow mesenchymal stem cells have a higher level of cellular senescence in older persons, resulting in a SASP-induced inflammatory environment causing disruption of factors indispensable for lymphocyte survival.
Sources: en.wikipedia.org
Neanderthal specimens vary in height from 147.5 to 177 cm (4 ft 10 in to 5 ft 10 in), with average male dimensions estimated at 165 cm (5 ft 5 in) and 75 kg (165 lb). While Neanderthal brain volume and ratio to body size averaged higher than any living human population — 1,640 cc (100 cu in) for males and 1,460 cc (89 cu in) for females — their brain organisation differed from modern humans in areas related to cognition and language, which could explain the comparative simplicity of Neanderthal behaviour to Cro-Magnons in the archaeological record. Neanderthals maintained a low population and suffered inbreeding depression, which may have impeded their ability to progress technologically. They produced Mousterian stone tools (a Middle Palaeolithic industry) and possibly wore blankets and ponchos. They maintained and might have created fire. They predominantly ate whatever was abundant close to home, usually big game as well as plants and mushrooms. Neanderthals were frequently victims of major physical traumas and animal attacks. Examples of Palaeolithic art have been inconclusively attributed to Neanderthals, namely possible ornaments made from bird claws and feathers; collections of unusual objects including crystals and fossils; and engravings. Neanderthals buried their dead, but there is no clear indication that they believed in life after death.
Today, it is widely planted in cities worldwide for its pollution tolerance and ornamental value. G. biloba wood is valued for its durability and used in crafts and sake-making, while its seeds are popular in Asian cuisine despite health risks, including potential carcinogenicity, allergic reactions, poisoning due to ginkgotoxin, drug interactions, and adverse effects such as bleeding and neurological symptoms, especially with excessive or improper use. Ginkgo-based products are widely marketed for cognitive benefits, although clinical research shows limited medical effectiveness except possibly for dementia, with approval in the European Union but not by the United States Food and Drug Administration.
== Further reading == Selassie CD (2003). "History of Quantitative Structure-Activity Relationships" (PDF). In Abraham DJ (ed.). Burger's medicinal Chemistry and Drug Discovery. Vol. 1 (6th ed.). New York: Wiley. pp. 1–48. ISBN 978-0-471-27401-8. Shityakov S, Puskás I, Roewer N, Förster C, Broscheit J (2014). "Three-dimensional quantitative structure-activity relationship and docking studies in a series of anthocyanin derivatives as cytochrome P450 3A4 inhibitors". Advances and Applications in Bioinformatics and Chemistry. 7: 11–21. doi:10.2147/AABC.S56478. PMC 3970920. PMID 24741320.
=== 1 February === At least 60 people were killed while 250 others were injured in an RSF attack on the Sabreen Market in Omdurman. Two others were killed in an SAF airstrike in Khartoum, while at least seven were killed by RSF shelling in El Obeid. Eleven people were killed by RSF shelling on the Abu Shouk camp, while 13 others were killed during clashes in Nyala. The SAF claimed to have retaken the cities of Tambul, Rufaa and Al-Hasahisa in Gezira State.
== Fetal vs adult healing in humans == Reparation of tissue in the mammalian fetus is radically different than the healing mechanisms observed in a healthy adult. During early gestation fetal skin wounds have the remarkable ability to heal rapidly and without scar formation. Wound healing itself is a particularly complex process and the mechanisms by which scarring occurs involves inflammation, fibroplasia, the formation of granulation tissue and finally scar maturation. Since the observation of scar free healing was first reported in the early fetus decades ago, research has focused intently on the underlying mechanisms which separate scarless fetal wound repair from normal adult wound healing. Scar free healing has been documented in fetuses across the animal kingdom, including mice, rats, monkeys, pigs, and humans. The ability of fetuses to heal without scarring is wound size dependent and also age-dependent, whereby after a specific gestational age, usually 24 weeks in humans, typical scar formation will occur. While the exact mechanisms of scar free healing in the fetus remain unknown, research has shown that it is thought to be due to the complex interaction of the components of the extracellular matrix (ECM), the inflammatory response, cellular mediators and the expression of specific growth factors.
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.